Price movement over the last 24 hours
Apartment Investment and Management Co vs Nuvalent Inc — how do they compare? Apartment Investment and Management Co trades at $2.86 (market cap $422.94M), while Nuvalent Inc trades at $123.81 (market cap $9.80B). The key difference: Nuvalent Inc is far larger — about 23.2× Apartment Investment and Management Co's market cap, and Nuvalent Inc is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.
| AIV | NUVL | |
|---|---|---|
Market Cap | $422.94M | $9.80B |
Sector | Real Estate | Technology |
52-Week High | $8.76 | $123.77 |
52-Week Low | $2.87 | $72.16 |
Enterprise Value | $669.06M | $8.51B |
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.94, down 0.68% on the day, with a bearish technical signal from moving averages. The company reported a net income of $554.01M for 2025, driven by a significant tax benefit, though revenue declined to $138.49M. Analyst consensus is mixed with 1 Buy and 2 Hold ratings. A $1.30 per share liquidating distribution is scheduled for June 2026, reflecting corporate restructuring efforts.
Outlook is cautious due to volatile earnings history and declining revenue, but the high net income margin and planned distribution offer some investor appeal. Key risks include inconsistent operational performance and high leverage, while institutional sentiment remains neutral pending clearer growth catalysts.
Nuvalent (NUVL) trades at $123.72, down slightly by 0.01% on the day, with a price-to-book ratio of 8.34. The stock exhibits a bullish technical trend, supported by strong moving averages, though RSI levels indicate overbought conditions. Recent financials show negative profitability, with a net loss of $425.38 million in 2025 and negative operating cash flow, but the company secured $515.34 million in financing. A major development is the pending $10.6 billion acquisition by GSK at $124 per share, announced in June 2026, which has driven significant investor attention and legal scrutiny over fairness.
The outlook for NUVL is heavily influenced by the GSK acquisition, offering a near-term exit at $124 per share. Risks include ongoing shareholder investigations into the deal's fairness and the company's persistent losses. Analyst sentiment is mixed, with 42% recommending buy and 58% hold, reflecting uncertainty around the acquisition's completion and valuation. Investors should monitor regulatory approvals and any competing offers that may emerge, as these will determine final shareholder returns.
Trailing returns across standard periods
Latest headlines on both assets
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →